PTCT Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PTC Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.24 |
| 52 Week High | US$54.16 |
| 52 Week Low | US$23.58 |
| Beta | 0.63 |
| 1 Month Change | 10.20% |
| 3 Month Change | 26.20% |
| 1 Year Change | 67.48% |
| 3 Year Change | 10.46% |
| 5 Year Change | -5.27% |
| Change since IPO | 180.41% |
Recent News & Updates
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Price Is Right But Growth Is Lacking After Shares Rocket 29%
Dec 03
PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
Nov 29Recent updates
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Price Is Right But Growth Is Lacking After Shares Rocket 29%
Dec 03PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
Nov 29PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 09PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
Sep 12Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues
Jun 28PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna
May 22Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%
May 22PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
May 14PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Mar 03PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options
Feb 11An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Jun 23Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price
May 18An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued
Mar 02PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.
Oct 19Shareholder Returns
| PTCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | -5.6% | -3.5% |
| 1Y | 67.5% | -1.5% | 22.1% |
Return vs Industry: PTCT exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: PTCT exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| PTCT volatility | |
|---|---|
| PTCT Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PTCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PTCT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,022 | Matt Klein | www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.
PTC Therapeutics, Inc. Fundamentals Summary
| PTCT fundamental statistics | |
|---|---|
| Market cap | US$3.49b |
| Earnings (TTM) | -US$453.20m |
| Revenue (TTM) | US$900.66m |
4.0x
P/S Ratio-7.9x
P/E RatioIs PTCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTCT income statement (TTM) | |
|---|---|
| Revenue | US$900.66m |
| Cost of Revenue | US$601.30m |
| Gross Profit | US$299.37m |
| Other Expenses | US$752.57m |
| Earnings | -US$453.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.88 |
| Gross Margin | 33.24% |
| Net Profit Margin | -50.32% |
| Debt/Equity Ratio | -224.5% |
How did PTCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PTC Therapeutics, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Huidong Wang | Barclays |
| Geoffrey Meacham | Barclays |